Insider Selling: Illumina, Inc. (ILMN) EVP Sells 2,000 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $242.33, for a total transaction of $484,660.00. Following the transaction, the executive vice president now directly owns 29,815 shares in the company, valued at $7,225,068.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Marc Stapley also recently made the following trade(s):

  • On Monday, December 4th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $219.88, for a total transaction of $439,760.00.
  • On Wednesday, November 15th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00.
  • On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $206.88, for a total transaction of $413,760.00.

Shares of Illumina, Inc. (ILMN) traded down $0.74 during midday trading on Thursday, hitting $241.31. 755,046 shares of the stock were exchanged, compared to its average volume of 893,849. The firm has a market capitalization of $35,230.00, a PE ratio of 45.53, a price-to-earnings-growth ratio of 3.24 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina, Inc. has a 1-year low of $156.50 and a 1-year high of $248.97.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.97 earnings per share. equities research analysts expect that Illumina, Inc. will post 3.76 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Advisory Services Network LLC increased its position in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Dupont Capital Management Corp acquired a new stake in Illumina during the third quarter worth about $153,000. Patten Group Inc. increased its position in Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after purchasing an additional 615 shares during the last quarter. West Coast Financial LLC acquired a new stake in Illumina during the third quarter worth about $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Illumina during the second quarter worth about $226,000. Institutional investors and hedge funds own 91.60% of the company’s stock.

Several equities analysts have issued reports on ILMN shares. Barclays increased their price objective on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective on the stock in a report on Friday, October 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $226.00 price objective (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Finally, Janney Montgomery Scott raised shares of Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $220.13.

ILLEGAL ACTIVITY WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/18/insider-selling-illumina-inc-ilmn-evp-sells-2000-shares-of-stock.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply